– December 1, 2005
December 1, 2005
View Issues
-
Pharmacology Watch
Beta-Blockers Therapy for the Treatment of Hypertension; Treatments for Acute Migraine; Statin Therapy for ACS Patients; The Correct Dosing for Onychomycosis; FDA Actions -
Clinical Briefs in Primary Care supplement
-
Bevacizumab with Gemcitabine Shows Activity in Phase II Pancreatic Cancer Trial
In a phase II trial of bevacizumab and gemcitabine in patients with advanced pancreatic cancer, responses were observed in 21% and stable disease in 46%. Although the median overall survival was not dramatically superior to that reported for gemcitabine alone, there is rationale for proceeding to larger scale phase III trial of this combination. -
Heparin-Induced Thrombocytopenia with Low Molecular Weight Heparin
In this prospective study of 1754 medical patients receiving low molecular weight heparin (LMWH), Prandoni and colleagues found a 0.8% incidence of heparin induced thrombocytopenia. The incidence was similar to a prior study they performed in medical patients receiving unfractionated heparin (UFH). Prior heparin exposure was associated with an increased risk of HIT. These data raise the possibility that HIT occurs more commonly in medical patients than previously appreciated and the incidence may not necessarily be significantly lower than with UFH. Clinicians must remain aware of the possibility of HIT, even in patients receiving either LMWH or UFH. -
Routine Surgical Staging in Grade 1 Endometrial Cancer Appears Beneficial
Surgical staging in patients presenting with grade 1 endometrial cancer significantly impacted postoperative treatment decisions in 29% of patients. Omitting lymphadenectomy in patients presenting with grade 1 endometrial cancer may lead to inappropriate postoperative management. -
Randomized Trial First to Demonstrate a Survival Benefit in Patients with Recurrent Cervical Cancer
Despite increased toxicity, CT did not significantly reduce patient QOL when compared with cisplatin alone. Patient-reported QOL measures may be an important prognostic tool in advanced cervix cancer. -
Proteomic Profiling in Ovarian Cancer: Is it Plausible?
The reproducibility of the proteomic profiling approach has yet to be established.